We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lowered Blood Pressure Acceptable as Surrogate Endpoint in Trials
Lowered Blood Pressure Acceptable as Surrogate Endpoint in Trials
February 18, 2009
Sponsors of hypertension drugs may use a reduction in blood pressure as a surrogate endpoint in clinical trials, but the real goal must be to reduce mortality and cardiovascular morbidity, the European Medicines Agency (EMEA) says.